Breast Cancer Resistance Protein Expression and 5-Fluorouracil Resistance  

作　　者：JIAN-HUI YUAN JIN-QUAN CHENG LONG-YUAN JIANG WEI-DONG JI LIANG-FENG GUO JIAN-JUN LIU XING-YUN XU JING-SONG HE XIAN-MING WANG ZHI-XIONG ZHUANG 

机构地区：[1]Faculty of Preventive Medicine, School of Public Health, Sun Yat-Sen University, Guangzhou 510080,Guangdong, China [2]Toxicology Laboratory, Municipal Center for Disease Control and Prevention,Shenzhen 518020 Guangdong, China [3]Department of Emergency, The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510120, Guangdong, China [4]Department of General Surgery, Shenzhen Second People＇s Hospital, Shenzhen 518035, Guangdong, China

出　　处：《Biomedical and Environmental Sciences》2008年第4期290-295,共6页生物医学与环境科学（英文版）

基　　金：the National Basic Research Program of China (No. 2002CB512903);the National Natural Science Foundation of China (No. 30500599)

摘　　要：Objective To filtrate breast cancer resistance protein （BCRP）-mediated resistant agents and to investigate clinical relationship between BCRP expression and drug resistance. Methods MTT assay was performed to filtrate BCRP-mediated resistant agents with BCRP expression cell model and to detect chemosensitivity of breast cancer tissue specimens to these agents. A high performance liquid chromatography （HPLC） assay was established, and was used to measure the relative dose of intracellular retention resistant agents. RT-PCR and immunohistochemistry （IHC） were employed to investigate the BCRP expression in breast cancer tissue specimens. Results MTT assay showed that the expression of BCRP increased with the increasing resistance of 5-fluorouracil （5-Fu） （P〈0.05, n=3） in the cell model, while HPLC assay indicated that the intracellular retention dose of 5-Fu was significantly correlated with the expression of BCRP （t=-0.897, P〈0.05, n=3）. A total of 140 breast cancer tissue specimens were collected. BCRP-positive expression was detected in forty-seven specimens by both RT-PCR and IHC. As shown by MTT assay subsequently, the resistance index （RI） of 47 BCRP-positive breast cancer tissue specimens to 5-Fu was 7-12 times as high as that of adjacent normal tissue samples. BCRP expression was related to 5-Fu resistance （R2=0.8124, P〈0.01）. Conclusion Resistance to 5-Fu can be mediated by BCRR Clinical chemotherapy for breast cancer patients can be optimized based on BCRP-positive expression.Objective To filtrate breast cancer resistance protein （BCRP）-mediated resistant agents and to investigate clinical relationship between BCRP expression and drug resistance. Methods MTT assay was performed to filtrate BCRP-mediated resistant agents with BCRP expression cell model and to detect chemosensitivity of breast cancer tissue specimens to these agents. A high performance liquid chromatography （HPLC） assay was established, and was used to measure the relative dose of intracellular retention resistant agents. RT-PCR and immunohistochemistry （IHC） were employed to investigate the BCRP expression in breast cancer tissue specimens. Results MTT assay showed that the expression of BCRP increased with the increasing resistance of 5-fluorouracil （5-Fu） （P〈0.05, n=3） in the cell model, while HPLC assay indicated that the intracellular retention dose of 5-Fu was significantly correlated with the expression of BCRP （t=-0.897, P〈0.05, n=3）. A total of 140 breast cancer tissue specimens were collected. BCRP-positive expression was detected in forty-seven specimens by both RT-PCR and IHC. As shown by MTT assay subsequently, the resistance index （RI） of 47 BCRP-positive breast cancer tissue specimens to 5-Fu was 7-12 times as high as that of adjacent normal tissue samples. BCRP expression was related to 5-Fu resistance （R2=0.8124, P〈0.01）. Conclusion Resistance to 5-Fu can be mediated by BCRR Clinical chemotherapy for breast cancer patients can be optimized based on BCRP-positive expression.

关 键 词：Breast cancer resistance protein 5-FLUOROURACIL Breast cancer RESISTANCE CHEMOTHERAPY 

分 类 号：R737.9[医药卫生—肿瘤]